The inhibition of noscapine to CYP3A4 and CYP2C9: explanation for clinical DDI between noscapine and warfarin

被引：0
|
作者：
Fang, Zhong-Ze [1 ]
Yang, Ling [1 ]
机构：
[1] Chinese Acad Sci, Dalian Inst Chem Phys, Lab Pharmaceut Resource Discovery, Dalian 116023, Peoples R China
来源：
DRUG METABOLISM REVIEWS | 2009年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
150
引用
收藏
页码：74 / 74
页数：1
相关论文
共 50 条
  • [41] CYP3A4, CYP2C9 and CYP2B6 expression and ifosfamide turnover in breast cancer tissue microsomes
    R Schmidt
    F Baumann
    H Knüpfer
    M Brauckhoff
    L-C Horn
    M Schönfelder
    U Köhler
    R Preiss
    British Journal of Cancer, 2004, 90 : 911 - 916
  • [42] The expression of CYP2B6, CYP2C9 and CYP3A4 genes: a tangle of networks of nuclear and steroid receptors
    Pascussi, JM
    Gerbal-Chaloin, S
    Drocourt, L
    Maurel, P
    Vilarem, W
    BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS, 2003, 1619 (03): : 243 - 253
  • [43] CYP3A4, CYP2C9 and CYP2B6 expression and ifosfamide turnover in breast cancer tissue microsomes
    Schmidt, R
    Baumann, F
    Knüpfer, H
    Brauckhoff, M
    Horn, LC
    Schönfelder, M
    Köhler, U
    Preiss, R
    BRITISH JOURNAL OF CANCER, 2004, 90 (04) : 911 - 916
  • [44] The Effects of Panax Notoginseng Saponins (PNS) on the Activities of 'Rat' CYP2C9, CYP2D6 and CYP3A4
    Iba, Michael M.
    PHYTOTHERAPY RESEARCH, 2014, 28 (01) : 150 - 151
  • [45] Relationships between CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 metabolic phenotypes and genotypes in a Nicaraguan Mestizo population
    Fernando de Andrés
    Catalina Altamirano-Tinoco
    Ronald Ramírez-Roa
    Carlos F Montes-Mondragón
    Pedro Dorado
    Eva M. Peñas-Lledó
    Adrián LLerena
    The Pharmacogenomics Journal, 2021, 21 : 140 - 151
  • [46] Effect of Dihydromyricetin on Cytochrome P450 Isoforms CYP1A2, CYP2C9 and CYP3A4 in Rats
    Huang, Yi
    Xu, Zhi-sheng
    Ye, Qiang
    LATIN AMERICAN JOURNAL OF PHARMACY, 2013, 32 (10): : 1570 - 1574
  • [47] Mutations of the CYP2C9 gene and the response to warfarin
    Yasar, U
    Oscarson, M
    Eliasson, E
    Sjöqvist, F
    SURGERY, 2001, 129 (03) : 384 - 384
  • [48] CYP2C9 polymorphism and warfarin dose requirements
    Daly, AK
    Day, CP
    Aithal, GP
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 53 (04) : 408 - 409
  • [49] CYP2C9 polymorphism affects warfarin complications
    Reactions Weekly, 1999, 741 (1) : 4 - 4
  • [50] Warfarin therapy is feasible in CYP2C9*3 homozygous patients
    Ablin, J
    Cabili, S
    Eldor, A
    Lagziel, A
    Peretz, H
    THERAPEUTIC DRUG MONITORING, 2005, 27 (02) : 238 - 238
12345